Insulin needs after CD3-antibody therapy in new-onset type 1diabetes

Article Abstract:

A study was conducted to assess the daily insulin needs and residual beta-cell function according to glucose-clamp-induced C-peptide release before and after the administration of glucagon. The result showed that short-term treatment with CD3 antibody preserves residual beta-cell function for at least 18 months in patients with recent-onset type 1 diabetes.

Drug therapy, Type 1 diabetes, Dosage and administration, Insulin

---

Case 4-2005: A 35-year-old man with nasal congestion, swelling, and pain

Article Abstract:

A case of 35-year-old man is presented who was admitted in the emergency department of Massachusetts General Hospital because of nasal congestion, swelling, and pain in his right nostril. The patient had the signs and symptoms of nasal ulceration and inflammation whose potential causes involve a broad range of both infectious and noninfectious causes.

Care and treatment, Diagnosis, Causes of, Respiratory tract infections

---

Similar abstracts:

• Abstracts: Tailoring arthritis therapy in the wake of the NSAID crisis
• Abstracts: Incidence of end-stage renal disease in patients with type 1 diabetes. Isolated pancreas transplantation for type 1 diabetes: a doctor's dilemma
• Abstracts: Your fitness tool kit: the rowing machine. Dancing for absolute beginners. Take your diet to work
• Abstracts: Power-sharing brings greater satisfaction. Choice in the diet of people with learning difficulties. Access to secondary care for people with learning disabilities
• Abstracts: Etanercept plus standard therapy for Wegener's granulomatosis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.